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Abstract
Background: Hypertension is a leading cause of cardiovascular disease, stroke, and death. It affects a substantial
proportion of the population worldwide, and remains underdiagnosed and undertreated.
Body: Long-standing high blood pressure leads to left ventricular hypertrophy and diastolic dysfunction that cause
an increase in myocardial rigidity, which renders the myocardium less compliant to changes in the preload,
afterload, and sympathetic tone. Adequate blood pressure control must be achieved in patients with hypertension
to prevent progression to overt heart failure. Controlling blood pressure is also important in patients with
established heart failure, especially among those with preserved ejection fractions. However, aggressive blood
pressure lowering can cause adverse outcomes, because a reverse J-curve association may exist between the blood
pressure and the outcomes of patients with heart failure. Little robust evidence exists regarding the optimal blood
pressure target for patients with heart failure, but a value near 130/80 mmHg seems to be adequate according to
the current guidelines.
Conclusion: Prospective studies are required to further investigate the optimal blood pressure target for patients
with heart failure.
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Background
Hypertension (HTN) affects a substantial portion of the
population worldwide, more than 7.5 million deaths per
year are attributable to HTN [1], and HTN is the single
most important contributor to mortality and morbidity.
Individuals with high blood pressure (BP) are more sus-
ceptible to ischemic heart disease, and studies’ findings
have shown that these patients may have a six-fold
greater risk of a myocardial infarction [2]. HTN is also
associated with the prevalence of atrial fibrillation [3]
and ventricular arrhythmias [4]. Indeed, among those
who participated in the Framingham Heart Study and
not having histories of HTN and cardiovascular (CV)
disease (n = 6859), the risk of developing CV disease in
individuals with BPs ≥ 130/85mmHg was almost triple
that of participants with BPs < 120/80 mmHg [5]. In
addition, diabetes and dyslipidemia frequently coexist
with HTN [6, 7], which further increase the risk of CV
disease.
The findings from different trials have demonstrated
an association between long-standing HTN and heart
failure (HF). A meta-analysis of 23 BP-lowering trials
showed that 28.9% of the patients developed HF, which
amounted to 8.5 events per 1000 patients [8]. Of the in-
dividuals in the Framingham Heart Study cohort, 91% of
the participants with HF had a previous diagnosis of
HTN, and compared with the normotensive individuals,
the male and female patients with HTN had 2- and 3-
fold increased risks, respectively, of developing HF [2].
Furthermore, the population-attributable risks of HF
were 39 and 59% for the male and female participants,
respectively [2], and the risk was even higher for the
older individuals, with HF being attributable to elevated
BP in up to 68% of the patients [9].
Chronic HTN causes structural and functional changes
in the heart that ultimately lead to HF, which further in-
creases mortality and morbidity. Although treating high
BP intensively prevents and reverses myocardial changes
in patients at risk of HF, defining the optimal BP target for
patients with established HF is challenging, because the
evidence is inconsistent and scarce. In this brief review,
we aim to provide an insight into the pathophysiology of
hypertensive heart disease and to summarize the current
evidence relating to BP control in the prevention and
treatment of HF.
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Pathophysiology of hypertensive heart disease
High BP increases the left ventricular (LV) afterload and
peripheral vascular resistance, and prolonged exposure
to an increased load leads to pressure- and volume-
mediated LV structural remodeling [2, 10]. Ventricular
hypertrophy is an initial compensatory mechanism in re-
sponse to the chronic pressure overload that preserves
the cardiac output and delays cardiac failure. However,
the remodeled left ventricle is likely to decompensate,
and HF can develop as a consequence of increased LV
stiffness and the presence of diastolic dysfunction [11].
Diastolic dysfunction is one of the first changes ob-
served in a heart that has been exposed to an increased
load. In response to LV end-diastolic pressure elevations,
the left ventricle becomes hypertrophied and more rigid,
and additional changes are induced by neurohormonal
pathways activated by the BP increase [12]. Ventricular
hypertrophy can be divided into either concentric or ec-
centric hypertrophy by relative wall thickness (RWT).
Concentric hypertrophy (RWT > 0.42) is associated with
an increase in the thickness of the LV wall, while eccentric
hypertrophy (RWT ≤0.42 is defined by the dilatation of
the LV chamber [13]. A long-standing pressure overload
is more likely to develop into concentric hypertrophy,
while a volume overload is associated with eccentric
hypertrophy. In chronic HTN, which involves both pres-
sure and volume overloads, the LV hypertrophy can be
concentric or eccentric, and these types are associated
with HF with a preserved ejection fraction (HFpEF) and
HF with a reduced ejection fraction (HFrEF), respectively.
Demographic factors affect the response of the ventricle;
hence, black patients are more likely than white patients
to have concentric responses [14], and female and older
patients are more prone to concentric changes [15, 16].
Patients with isolated systolic HTN and those with higher
systolic BPs (SBPs) and ambulatory BPs are also more
likely to exhibit concentric hypertrophy [17, 18]. Comor-
bid conditions can also affect the patterns of hypertrophy.
For example, patients with diabetes are more prone to
concentric changes [19], while patients with coronary
artery disease and those who are obese are more likely to
exhibit eccentric remodeling [20, 21]. Furthermore, the ac-
tivation of neurohormonal pathways, including the renin-
angiotensin system and the sympathetic nervous system
[22], and extracellular matrix alterations induce changes
in the ventricular mass and dimension [23].
Hypertensive HF primarily manifests as diastolic dys-
function, followed by concentric or eccentric LV hyper-
trophy. Diastolic dysfunction increases the LV filling
pressure and left atrial (LA) volume, which, in turn, in-
crease the pulmonary artery pressure [24].
The pathway from LV hypertrophy to overt HF is
complex and unclear. Most patients with concentric
hypertrophy develop HFpEF, but despite the absence of
a history of myocardial infarction, some can progress to
HFrEF. The development of HFpEF seems to be associ-
ated with changes in the extracellular matrix that cause
progressive fibrosis of the myocardium and, subsequently,
an increase in LV stiffness [25]. It is also possible that
patients with eccentric LV hypertrophy will progress to
either HFpEF or HFrEF. The changes in the heart caused
by HTN were categorized over 25 years ago [12, 26], as
follows: degree I: asymptomatic patients without LV
hypertrophy, but with LV diastolic dysfunction; degree II:
asymptomatic or mildly symptomatic patients with LV
hypertrophy; degree III: clinical HF with a preserved ejec-
tion fraction (EF); and degree IV: dilated cardiomyopathy
or HFrEF.
Prognosis of patients with left ventricular hypertrophy
Cardiac structural changes are mostly caused by a chronic
rise in the BP, and they are markers of preclinical or asymp-
tomatic CV disease [27]. The presence of an LV strain pat-
tern, that is, LV hypertrophy, on a 12-lead electrocardiogram
is an independent predictor of the CV outcome [28]. The
findings from two-dimensional echocardiography suggest
that LV hypertrophy is a significant predictor of mortality
[29]. The Framingham Heart Study’s findings showed that
the incidence of CV events was significantly higher among
the patients with an LV mass index (LVMI) > 125 g/m2 than
that among the patients with normal LVMIs [30]. Ventricu-
lar hypertrophy is also a major predictor of stroke and renal
outcomes [31]. Echocardiography can also detect diastolic
dysfunction, and it provides information about chamber
geometry and systolic function. Three-dimensional
echocardiography and magnetic resonance imaging
provide more reliable measurements of ventricular
geometry and function, but less evidence is available
regarding patients’ prognoses [32].
Pulmonary edema
Patients with long-standing HTN are more sensitive to
changes in pressure, volume, and sympathetic tone [33].
Although decompensated HF is usually considered a
volume-overloaded state provoked by poor systolic func-
tion, the excess volume may not always be required for a
patient to present with HF in those with LV hypertrophy
and diastolic dysfunction. The reduced compliance of
the ventricle and systemic vasculature in patients with
hypertensive HF results in abnormal ventricular-vascular
interactions [34]. The premature return of aortic pulse
waves increases the resistance to the ventricular outflow,
which, in turn, impedes the pulmonary venous flow to-
wards the heart [33]. Consequently, small changes in the
preload, afterload, or sympathetic tone can further in-
crease the LV filling pressure, thereby disrupting the
pulmonary capillary blood-gas barrier, which leads to
flash pulmonary edema [12].
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Hypertensive acute HF occurs when adverse condi-
tions result in a volume redistribution and a shift from
the splanchnic and peripheral vasculature to the pul-
monary circulation. This ventricular-vascular uncoupling
manifests as a rapid onset of pulmonary edema in pa-
tients with LV hypertrophy and diastolic dysfunction.
Although intravenous diuretics are the first choice in
treating acute HF with volume overload (Class I), redu-
cing the preload and afterload using vasodilators (Class
IIa, LOE B) should be also considered, as the volume
overload might not be involved in the clinical congestion
in some patients [33]. Residual pulmonary congestion
persists in 30–40% of patients after hospital treatment
[35], which suggests that relatively euvolemic patients
require adequate diagnoses and treatment of pulmonary
edema.
Prevalence of hypertension among heart failure patients
The prevalence of HTN as an HF etiology varies geo-
graphically and temporally (Table 1). The findings from
the Korean Heart Failure (KorHF) study, which recruited
3200 patients with HF from 2004 to 2009, showed that
36.7% of the patients had hypertensive HF [37]. More re-
cently, the findings from the Korean Acute Heart Failure
(KorAHF) study, which enrolled 5625 patients from
2011 to 2014, showed that only 4% of the patients had
HF caused by HTN [36]. Up to 30% of the patients in
the Acute Decompensated Heart Failure National
Table 1 Comparison of dedicated heart failure registries
KorAHF [36] KorHF [37] ASIAN-HF [38] ATTEND [39] ADHERE [40, 41] ESC-HF-LT [42]
2011–2014 2004–2009 2012–2015 2007–2011 2002–2004 2011–2013
N 5625 3200 5276 4837 159,168 4449
Age, years (SD) 68.5 (14.5) 67.6 (14.3) 59.6 (13.1) 73.0 (13.8) 72.4 (14.1) 69.4 (13.0)
Male, % 53.2 55.9 78.2 57.9 48.4 62.6
BMI, kg/m2 23.3 (3.9) 23.2 (4.0) 24.9 (5.1) 28.7 (5.4)
NYHA class III-IV, % 84.8 74.0 35 81.4 76 85.2
SBP, mmHg 131.2 (30.3) 130.5 (3.2) 118.4 (20.2) 145.5 (36.7) 143.9 (33.2) 133.5 (28.2)
DBP, mmHg 78.6 (18.8) 77.9 (18.0) 72.4 (12.6) 82.6 (22.6) 77.7 (20.2)
HR, beats/minute 92.6 (26.0) 91.2 (25.4) 79.7 (16.2) 98.6 (29.1) 90.8 (25.3)
EF, % 37.7 ± 15.6 38.5 ± 15.7 28 [22, 33] 53.4% with
EF <40%
37.8 ± 17.3 39.0 [30, 43]
Etiology (%)
- Hypertension 4.0 36.7 18 Up to 30%
in EF ≥ 55%
8.2
- Ischemic heart disease 37.6 52.3 47.0 31.1 56.5
Medical history (%)
- Hypertension 62.2 46.5 51.9 69.3 73.9 65.6
- Ischemic heart disease 42.9 50.2 57.5 53.8
- Diabetes mellitus 40.0 30.5 40.4 36.2 44 39.0
- Atrial fibrillation / atrial flutter 28.5 20.8 17.9 39.6 30.9 44.0
- Renal insufficiency 14.3 9.2 30.1 25.3
- Stroke / transient ischemic attack 15.2 18.9 6.4 14.0 12.5
- Chronic lung disease 11.3 3.5 8.3 9.5 31.4 20.1
- Previous heart failure 47.8 29.6 64.1 36.1 75.6 70.9
Medications at discharge
- ACE inhibitor 29.5 17.9 51.0 70–75 83.1 77.0
- Angiotensin receptor blocker 39.7 39.4 26.9
- Beta blocker 49.9 58.6 78.8 67 80.1 72.6
- Aldosterone antagonist 44.9 53.1 59.4 40–50 32.8 53.9
- Diuretic 68.1 81.5 87.2 83.9
SD standard deviation, BMI body mass index, NYHA New York heart association functional class, SBP systolic blood pressure, DBP diastolic blood pressure, EF
ejection fraction, ACE angiotensin converting enzyme
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Registry (ADHERE) had a hypertensive etiology, and this
was more prevalent among the patients with normal EFs
[44]. The results from studies of other large dedicated
HF registries have shown that HTN was the primary
cause of HF in 11–23% of the patients [45, 46].
In contrast, the presence of HTN as a comorbid con-
dition in patients with HF has become more pronounced
over time. The findings from studies of the KorHF and
KorAHF registries showed that the prevalence of HTN
increased from 47 to 59% over 10 years [36, 37]. The
findings from a study of the ADHERE showed that 69%
of patients with HFrEFs and 77% of the patients with
HFpEFs had elevated BPs [47]. The frequent coexistence
of HTN and HF is observed across all regions. Indeed,
55.4% of the patients in the Asian Sudden Cardiac Death
in Heart Failure registry [38] and 65.6% of the patients
in the European Society of Cardiology Heart Failure
Long-Term registry [42] were diagnosed with HTN and
HF. Insurance claims data from the United States of
America suggest that HTN was the most commonly co-
occurring clinical condition among Medicare beneficiar-
ies with HF [48].
Whether HTN is a cause or a contributor to the devel-
opment of HF is not clear. Although a BP elevation
alone may not be sufficient to trigger HF, it increases
the risk of CV diseases progressing to HF. For example,
the activation of neurohormonal pathways induced by a
persistent BP elevation in addition to LV hypertrophy
could lead to adverse modifications of postinfarct ven-
tricular remodeling, rendering the heart vulnerable to the
development of HF after a myocardial infarction [49]. Fac-
tors, including an increased afterload, reduced arterial
compliance, and the lack of a response to vasodilators,
also affect cardiac output in the context of HF [50].
Blood pressure and heart failure prevention
Two issues arise regarding HF when treating HTN. The
first is strictly controlling high BP to prevent structural
remodeling and the development of HF. The presence of
a J-curve association between BP and CV outcomes have
been long debated, but evidence has been controversial
[51, 52]. The current consensus is that strict control is
mostly beneficial for hypertensive patients with low CV
risk, while the risk of CV outcome increases in patients
with high risk for coronary heart disease [53]. Recently,
the findings from the Systolic Blood Pressure Interven-
tion Trial (SPRINT), which assessed the role of intensive
HTN treatment on a composite outcome that included
HF, showed that a target SBP < 120 mmHg was associ-
ated with a 38% relative risk reduction in HF [54]. BP
lowering in patients with ventricular hypertrophy can
delay further remodeling and reduce the incidence of
HF [55]. The LV hypertrophy induced by HTN is not
unidirectional, and a regression of LV mass has been
observed after the pharmacological treatment of elevated
BP [43]. Improvements in LV hypertrophy have also
been associated with reduced risks of CV events, includ-
ing CV death, myocardial infarction, and stroke [56].
Identifying patients at an increased risk of developing
hypertensive HF is important to enable attentive moni-
toring and begin timely treatment. LA enlargement in
the absence of mitral valve disease could be a marker of
diastolic dysfunction; this has been demonstrated by the
correlation between the LA volume and the natriuretic
peptide levels in asymptomatic patients with preserved
systolic function [57]. Biomarkers such as uric acid, me-
talloproteinases, and natriuretic peptides, may also pre-
dict the development of HF in patients with HTN [58].
Patients with HTN and a high clinical risk of HF should
be screened regularly for diastolic dysfunction or LV
hypertrophy to prevent progression to advanced disease.
HTN treatment relies on many classes of drugs, including
angiotensin-converting enzyme (ACE) inhibitors/angioten-
sin receptor blockers (ARBs), beta-blockers, calcium chan-
nel blockers (CCBs), and diuretics. A meta-analysis of
randomized clinical trials that analyzed HF as an outcome
showed significant reductions in the new-onset HF rates in
association with all of these classes of drug, except for
ARBs, which may have been a consequence of the small
number trials reviewed. The findings from head-to-head
comparisons of the different drug classes have shown that
CCBs seem to be inferior at preventing HF compared with
ACE inhibitors/ARBs, beta-blockers, and diuretics; how-
ever, the inferiority of the CCBs was largely attributable to
differences in the use of concomitant drugs [59]. Thiazide-
like diuretics, which are widely used to treat HTN, but are
not frequently used in patients with HF, also reduced the
new-onset HF rate compared with placebo [60], which
suggests that reducing the BP itself is probably the most
important factor in HF prevention. Indeed, for every
10mmHg reduction in SBP, the HF rate declines by 12%
[54]. Currently, no specific class of drugs is recommended
for the prevention of HF in patients with HTN, and pa-
tients should be treated according to the guidelines [61].
Treatment of hypertension in patients with heart failure:
the J-curve phenomenon
The other issue regarding HF and HTN is managing
high BP in established HF patients. Treating high BP is
more complicated in patients with established HF, but it
remains important with respect to HF progression and
patients’ prognoses. As all medications that have favor-
able effects on HF outcomes lower BP to some extent,
we can assume that a close relationship exists between
BP and HF outcomes. However, data describing the opti-
mal BP in patients with HF are limited and contradict-
ory. The findings from the OPTIMIZE-HF (Organized
Program to Initiate Lifesaving Treatment in Hospitalized
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Patients with Heart Failure) trial suggested that BP ele-
vations in patients with HF were associated with lower
in-hospital mortality rates [46, 62]. A meta-analysis of
8000 patients with chronic HF also confirmed a trend
towards better outcomes in patients with higher BPs
[63]. Findings from the COPERNICUS (Carvedilol Pro-
spective Randomized Cumulative Survival) and CHARM
(Candesartan in Heart Failure: Assessment of Reduction
in Mortality and Morbidity) trials showed that the bene-
fits of these treatments persisted, regardless of a patient’s
BP, but the statistical significance of the findings was
marginal among the patients with lower BPs [64, 65].
Finally, the PARADIGM (Prospective Comparison of
angiotensin receptor-neprilysin inhibitor (ARNI) with an
angiotensin-converting enzyme (ACE) inhibitor to De-
termine Impact on Global Mortality and Morbidity in
Heart Failure) study findings show that, although the
benefit of sacubitril/valsartan over enalapril was still evi-
dent in patients with SBP < 120 mmHg, it was
significantly more decreased than those with SBP ≥120
mmHg [66]. However, the findings of a recent prospect-
ive cohort study has demonstrated that a higher SBP,
diastolic BP, and pulse pressure were associated with
higher rates of adverse events among patients with inci-
dent HF [67].
The relationship between BP and the HF prognosis is
not necessarily always linear. A J-curve that is similar to
that which describes the relationship between the BP
and CV outcomes, has been indicated repeatedly in pa-
tients with HTN [68–70]. The findings from a study of
the KorAHF registry showed that a reverse J-curve rela-
tionship was evident between the treatment of BP and
the outcomes of patients who were hospitalized for HF
[71], and that the risks of mortality and readmission
increased at low and high BPs, with similar trends for
patients with HFrEFs and HFpEFs (Fig. 1).
The trade-off between prescribing adequate doses of
guideline-directed medical treatments and maintaining a
Fig. 1 Restricted Cubic Splines Model for All-Cause Mortality According to On-Treatment BP. a SBP: all population. b SBP: heart failure with
reduced ejection fraction (EF). c SBP: heart failure with preserved EF. d DBP: all population. e DBP: heart failure with reduced EF (EF). f DBP: heart
failure with preserved EF. SBP, systolic blood pressure; DBP, diastolic blood pressure. Reprinted from JACC: Heart Failure, Vol 5, Lee SE, et al.,
Reverse J-Curve Relationship Between On-Treatment Blood Pressure and Mortality in Patients With Heart Failure, 810–819 No.11, 2017, with
permission from Elsevier [36]
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lower BP threshold is an issue that many physicians
encounter in daily practice. The benefits of treatment
in relation to the outcomes must be weighed against
the adverse effects induced by lower BPs. Although
medications with survival benefits remain effective
within lower BP thresholds, no definitive evidence is
available that supports intensive BP treatment. The
current evidence suggests that all patients with HF
should receive triple therapy comprising ACE inhibi-
tors or ARBs, beta-blockers, and diuretics, with the
doses adjusted to maintain an adequate BP, and if a
patient remains hypertensive, thiazide-like diuretics
can be added [12]. Based on the available evidence,
the Korean Society of Hypertension’s guidelines rec-
ommend an optimal BP that is close to 130/80 mmHg
when treating patients with established HF [61].
Conclusion
Among patients with chronic HTN, structural and func-
tional changes in the heart can lead to the development
of HF. BP management not only prevents asymptomatic
HTN-mediated organ damage that can cause HF but
can also prevent further disease progression. The inten-
sive control of BP is recommended for patients with
HTN who are at risk of HF; however, the optimal range
within which BP should be controlled and the benefits
of intensive BP control in patients with established HF
remain unclear. Future randomized clinical trials are
warranted to understand the complex association be-
tween BP and patients’ prognoses in the context of HF
management.
Abbreviations
ACE: Angiotensin-converting enzyme; ADHERE: Acute Decompensated Heart
Failure National Registry; ARB: Angiotensin receptor blocker; BP: Blood
pressure; CCB: Calcium channel blocker; CV: Cardiovascular; EF: Ejection
fraction; HF: Heart failure; HFpEF: Heart failure with a preserved ejection
fraction; HFrEF: Heart failure with a reduced ejection fraction;
HTN: Hypertension; KorAHF: Korean Acute Heart Failure; KorHF: Korean Heart





GCO is a major contributor to analyzing published data and writing the
manuscript. HJC contributed in conceptualization of this review and in




Availability of data and materials
Not applicable.





The authors declare that they have no competing interests.
Received: 4 October 2019 Accepted: 14 November 2019
References
1. WHO. World Health Organization Global Health Observatory (GHO) data.
Available from: https://www.who.int/gho/mortality_burden_disease/life_
tables/situation_trends_text/en/. Accessed 18 Sept 2019.
2. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from
hypertension to congestive heart failure. JAMA. 1996;275:1557–62.
3. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis,
and predisposing conditions for atrial fibrillation: population-based
estimates. Am J Cardiol. 1998;82:2N–9N.
4. McLenachan JM, Henderson E, Morris KI, Dargie HJ. Ventricular arrhythmias
in patients with hypertensive left ventricular hypertrophy. N Engl J Med.
1987;317:787–92.
5. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, et al.
Impact of high-normal blood pressure on the risk of cardiovascular disease.
N Engl J Med. 2001;345:1291–7.
6. de Boer IH, Bangalore S, Benetos A, Davis AM, Michos ED, Muntner P, et al.
Diabetes and Hypertension: A Position Statement by the American Diabetes
Association. Diabetes Care. 2017;40:1273–84.
7. Otsuka T, Takada H, Nishiyama Y, Kodani E, Saiki Y, Kato K, et al.
Dyslipidemia and the Risk of Developing Hypertension in a Working-Age
Male Population. J Am Heart Assoc. 2016;5:e003053.
8. Tocci G, Sciarretta S, Volpe M. Development of heart failure in recent
hypertension trials. J Hypertens. 2008;26:1477–86.
9. Yamasaki N, Kitaoka H, Matsumura Y, Furuno T, Nishinaga M, Doi Y. Heart
failure in the elderly. Intern Med. 2003;42:383–8.
10. Kenchaiah S, Pfeffer MA. Cardiac remodeling in systemic hypertension. Med
Clin North Am. 2004;88:115–30.
11. Lazzeroni D, Rimoldi O, Camici PG. From Left Ventricular Hypertrophy to
Dysfunction and Failure. Circ J. 2016;80:555–64.
12. Messerli FH, Rimoldi SF, Bangalore S. The Transition From Hypertension to
Heart Failure: Contemporary Update. JACC Heart Fail. 2017;5:543–51.
13. Mȕller AL. Differences in Concentric Cardiac Hypertrophy and Eccentric
Hypertrophy. Cardiac Adaptations Advances in Biochemistry in Health and
Disease; 2013.
14. Kizer JR, Arnett DK, Bella JN, Paranicas M, Rao DC, Province MA, et al.
Differences in left ventricular structure between black and white
hypertensive adults: the Hypertension Genetic Epidemiology Network study.
Hypertension. 2004;43:1182–8.
15. Krumholz HM, Larson M, Levy D. Sex differences in cardiac adaptation to
isolated systolic hypertension. Am J Cardiol. 1993;72:310–3.
16. Chahal NS, Lim TK, Jain P, Chambers JC, Kooner JS, Senior R. New insights
into the relationship of left ventricular geometry and left ventricular mass
with cardiac function: A population study of hypertensive subjects. Eur
Heart J. 2010;31:588–94.
17. Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, et
al. Patterns of left ventricular hypertrophy and geometric remodeling in
essential hypertension. J Am Coll Cardiol. 1992;19:1550–8.
18. Devereux RB, James GD, Pickering TG. What is normal blood pressure?
Comparison of ambulatory pressure level and variability in patients with
normal or abnormal left ventricular geometry. Am J Hypertens. 1993;6:211S–
5S.
19. Palmieri V, Bella JN, Arnett DK, Liu JE, Oberman A, Schuck MY, et al. Effect of
type 2 diabetes mellitus on left ventricular geometry and systolic function
in hypertensive subjects: Hypertension Genetic Epidemiology Network
(HyperGEN) study. Circulation. 2001;103:102–7.
20. Zabalgoitia M, Berning J, Koren MJ, Stoylen A, Nieminen MS, Dahlof B, et al.
Impact of coronary artery disease on left ventricular systolic function and
geometry in hypertensive patients with left ventricular hypertrophy (the
LIFE study). Am J Cardiol. 2001;88:646–50.
21. Gottdiener JS, Reda DJ, Materson BJ, Massie BM, Notargiacomo A,
Hamburger RJ, et al. Importance of obesity, race and age to the cardiac
structural and functional effects of hypertension. The Department of
Oh and Cho Clinical Hypertension            (2020) 26:1 Page 6 of 8
Veterans Affairs Cooperative Study Group on Antihypertensive Agents. J Am
Coll Cardiol. 1994;24:1492–8.
22. du Cailar G, Pasquie JL, Ribstein J, Mimran A. Left ventricular adaptation to
hypertension and plasma renin activity. J Hum Hypertens. 2000;14:181–8.
23. Lopez B, Gonzalez A, Querejeta R, Larman M, Diez J. Alterations in the
pattern of collagen deposition may contribute to the deterioration of
systolic function in hypertensive patients with heart failure. J Am Coll
Cardiol. 2006;48:89–96.
24. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM.
Pulmonary hypertension in heart failure with preserved ejection fraction: a
community-based study. J Am Coll Cardiol. 2009;53:1119–26.
25. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH,
et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases:
relationship between changes in proteolytic determinants of matrix
composition and structural, functional, and clinical manifestations of
hypertensive heart disease. Circulation. 2006;113:2089–96.
26. Iriarte M, Murga N, Sagastagoitia D, Morillas M, Boveda J, Molinero E, et al.
Classification of hypertensive cardiomyopathy. Eur Heart J. 1993;14(Suppl J):
95–101.
27. Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the
evolution from risk factor exposure to development of morbid events.
Circulation. 1993;88:1444–55.
28. Pahor M, Guralnik JM, Ambrosius WT, Blair S, Bonds DE, Church TS, et al.
Effect of structured physical activity on prevention of major mobility
disability in older adults: the LIFE study randomized clinical trial. JAMA.
2014;311:2387–96.
29. Simone G, Izzo R, Chinali M, Marco MD, Casalnuovo G, Rozza F, et al. Does
Information on Systolic and Diastolic Function Improve Prediction of a
Cardiovascular Event by Left Ventricular Hypertrophy in Arterial
Hypertension? Hypertension. 2010;56:99–104.
30. Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric
patterns in the Framingham Heart Study. J Am Coll Cardiol. 1995;25:879–84.
31. Tsioufis C, Kokkinos P, Macmanus C, Thomopoulos C, Faselis C, Doumas M,
et al. Left ventricular hypertrophy as a determinant of renal outcome in
patients with high cardiovascular risk. J Hypertens. 2010;28:2299–308.
32. Perrone-Filardi P, Coca A, Galderisi M, Paolillo S, Alpendurada F, de Simone
G, et al. Noninvasive cardiovascular imaging for evaluating subclinical target
organ damage in hypertensive patients: a consensus article from the
European Association of Cardiovascular Imaging, the European Society of
Cardiology Council on Hypertension and the European Society of
Hypertension. J Hypertens. 2017;35:1727–41.
33. Collins S, Martindale J. Optimizing Hypertensive Acute Heart Failure
Management with Afterload Reduction. Curr Hypertens Rep. 2018;20:9.
34. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and
arterial stiffening in patients with heart failure and preserved ejection
fraction: implications for systolic and diastolic reserve limitations. Circulation.
2003;107:714–20.
35. Coiro S, Rossignol P, Ambrosio G, Carluccio E, Alunni G, Murrone A, et al.
Prognostic value of residual pulmonary congestion at discharge assessed by
lung ultrasound imaging in heart failure. Eur J Heart Fail. 2015;17:1172–81.
36. Lee SE, Lee HY, Cho HJ, Choe WS, Kim H, Choi JO, et al. Clinical
Characteristics and Outcome of Acute Heart Failure in Korea: Results from
the Korean Acute Heart Failure Registry (KorAHF). Korean Circ J. 2017;47:
341–53.
37. Choi DJ, Han S, Jeon ES, Cho MC, Kim JJ, Yoo BS, et al. Characteristics,
outcomes and predictors of long-term mortality for patients hospitalized for
acute heart failure: a report from the korean heart failure registry. Korean
Circ J. 2011;41:363–71.
38. Tromp J, Tay WT, Ouwerkerk W, Teng TK, Yap J, MacDonald MR, et al.
Multimorbidity in patients with heart failure from 11 Asian regions: A
prospective cohort study using the ASIAN-HF registry. PLoS Med. 2018;15:
e1002541.
39. Sato N, Kajimoto K, Asai K, Mizuno M, Minami Y, Nagashima M, et al. Acute
decompensated heart failure syndromes (ATTEND) registry. A prospective
observational multicenter cohort study: rationale, design, and preliminary
data. Am Heart J. 2010;159:949–55 e1.
40. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR,
Abraham WT, et al. Characteristics and outcomes of patients hospitalized for
heart failure in the United States: rationale, design, and preliminary
observations from the first 100,000 cases in the Acute Decompensated
Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209–16.
41. Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW,
Committee ASA, et al. Temporal trends in clinical characteristics,
treatments, and outcomes for heart failure hospitalizations, 2002 to
2004: findings from Acute Decompensated Heart Failure National
Registry (ADHERE). Am Heart J. 2007;153:1021–8.
42. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G,
Ruschitzka F, et al. European Society of Cardiology Heart Failure Long-
Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences
across regions. Eur J Heart Fail. 2016;18:613–25.
43. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-
analysis of the effects of treatment on left ventricular mass in essential
hypertension. Am J Med. 2003;115:41–6.
44. Sweitzer NK, Lopatin M, Yancy CW, Mills RM, Stevenson LW. Comparison
of clinical features and outcomes of patients hospitalized with heart
failure and normal ejection fraction (> or =55%) versus those with
mildly reduced (40% to 55%) and moderately to severely reduced (<
40%) fractions. Am J Cardiol. 2008;101:1151–6.
45. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP,
et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute
heart failure patients: description of population. Eur Heart J. 2006;27:
2725–36.
46. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM,
She L, et al. Systolic blood pressure at admission, clinical characteristics,
and outcomes in patients hospitalized with acute heart failure. JAMA.
2006;296:2217–26.
47. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC, Committee
ASA, et al. Clinical presentation, management, and in-hospital outcomes of
patients admitted with acute decompensated heart failure with preserved
systolic function: a report from the Acute Decompensated Heart Failure
National Registry (ADHERE) Database. J Am Coll Cardiol. 2006;47:76–84.
48. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al.
2013 ACCF/AHA guideline for the management of heart failure: executive
summary: a report of the American College of Cardiology Foundation/
American Heart Association Task Force on practice guidelines. Circulation.
2013;128:1810–52.
49. Richards AM, Nicholls MG, Troughton RW, Lainchbury JG, Elliott J, Frampton
C, et al. Antecedent hypertension and heart failure after myocardial
infarction. J Am Coll Cardiol. 2002;39:1182–8.
50. Yip GW, Fung JW, Tan YT, Sanderson JE. Hypertension and heart failure: a
dysfunction of systole, diastole or both? J Hum Hypertens. 2009;23:295–306.
51. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective SC.
Age-specific relevance of usual blood pressure to vascular mortality: a
meta-analysis of individual data for one million adults in 61 prospective
studies. Lancet. 2002;360:1903–13.
52. Mancia G, Schumacher H, Redon J, Verdecchia P, Schmieder R, Jennings
G, et al. Blood pressure targets recommended by guidelines and
incidence of cardiovascular and renal events in the Ongoing
Telmisartan Alone and in Combination With Ramipril Global Endpoint
Trial (ONTARGET). Circulation. 2011;124:1727–36.
53. Kjeldsen SE, Oparil S, Narkiewicz K, Hedner T. The J-curve phenomenon
revisited again: SPRINT outcomes favor target systolic blood pressure below
120 mmHg. Blood Press. 2016;25:1–3.
54. Group SR, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N
Engl J Med. 2015;373:2103–16.
55. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, et al.
Reduction of cardiovascular risk by regression of electrocardiographic
markers of left ventricular hypertrophy by the angiotensin-converting
enzyme inhibitor ramipril. Circulation. 2001;104:1615–21.
56. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS,
Papademetriou V, et al. Prognostic significance of left ventricular mass
change during treatment of hypertension. JAMA. 2004;292:2350–6.
57. Kim H, Jun DW, Cho YK, Nam CW, Han SW, Hur SH, et al. The correlation of
left atrial volume index to the level of N-terminal pro-BNP in heart failure
with a preserved ejection fraction. Echocardiography. 2008;25:961–7.
58. Gluba A, Bielecka-Dabrowa A, Mikhailidis DP, Wong ND, Franklin SS, Rysz
J, et al. An update on biomarkers of heart failure in hypertensive
patients. J Hypertens. 2012;30:1681–9.
59. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering
treatment. 6. Prevention of heart failure and new-onset heart failure--meta-
analyses of randomized trials. J Hypertens. 2016;34:373–84 discussion 84.
Oh and Cho Clinical Hypertension            (2020) 26:1 Page 7 of 8
60. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al.
Treatment of hypertension in patients 80 years of age or older. N Engl J
Med. 2008;358:1887–98.
61. Lee HY, Shin J, Kim GH, Park S, Ihm SH, Kim HC, et al. 2018 Korean Society
of Hypertension Guidelines for the management of hypertension: part II-
diagnosis and treatment of hypertension. Clin Hypertens. 2019;25:20.
62. Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M,
Greenberg BH, et al. Predictors of in-hospital mortality in patients
hospitalized for heart failure: insights from the Organized Program to
Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure
(OPTIMIZE-HF). J Am Coll Cardiol. 2008;52:347–56.
63. Raphael CE, Whinnett ZI, Davies JE, Fontana M, Ferenczi EA, Manisty CH, et
al. Quantifying the paradoxical effect of higher systolic blood pressure on
mortality in chronic heart failure. Heart. 2009;95:56–62.
64. Rouleau JL, Roecker EB, Tendera M, Mohacsi P, Krum H, Katus HA, et al.
Influence of pretreatment systolic blood pressure on the effect of carvedilol
in patients with severe chronic heart failure: the Carvedilol Prospective
Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol.
2004;43:1423–9.
65. Meredith PA, Ostergren J, Anand I, Puu M, Solomon SD, Michelson EL, et al.
Clinical outcomes according to baseline blood pressure in patients with a
low ejection fraction in the CHARM (Candesartan in Heart Failure:
Assessment of Reduction in Mortality and Morbidity) Program. J Am Coll
Cardiol. 2008;52:2000–7.
66. Bohm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP, et al.
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of
sacubitril/valsartan (LCZ696) in patients with chronic heart failure and
reduced ejection fraction: results from PARADIGM-HF. Eur Heart J. 2017;38:
1132–43.
67. Lip GY, Skjoth F, Overvad K, Rasmussen LH, Larsen TB. Blood pressure and
prognosis in patients with incident heart failure: the Diet, Cancer and
Health (DCH) cohort study. Clin Res Cardiol. 2015;104:1088–96.
68. Tsika EP, Poulimenos LE, Boudoulas KD, Manolis AJ. The J-curve in arterial
hypertension: fact or fallacy? Cardiology. 2014;129:126–35.
69. Lip S, Tan LE, Jeemon P, McCallum L, Dominiczak AF, Padmanabhan S.
Diastolic Blood Pressure J-Curve Phenomenon in a Tertiary-Care
Hypertension Clinic. Hypertension. 2019;74:767–75.
70. Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, et
al. J-curve revisited: An analysis of blood pressure and cardiovascular events
in the Treating to New Targets (TNT) Trial. Eur Heart J. 2010;31:2897–908.
71. Lee SE, Lee HY, Cho HJ, Choe WS, Kim H, Choi JO, et al. Reverse J-Curve
Relationship Between On-Treatment Blood Pressure and Mortality in
Patients With Heart Failure. JACC Heart Fail. 2017;5:810–9.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Oh and Cho Clinical Hypertension            (2020) 26:1 Page 8 of 8
